1. Late acute humoral rejection in low-risk renal transplant recipients induced with an interleukin-2 receptor antagonist and maintained with standard therapy: preliminary communication.
- Author
-
Morales J, Contreras L, Zehnder C, Pinto V, Elberg M, Araneda S, Herzog C, Calabran L, Aguiló J, Ferrario M, Buckel E, and Fierro JA
- Subjects
- Acute Disease, Adult, Basiliximab, Chile, Communicable Diseases etiology, Female, Graft Rejection immunology, Graft Rejection mortality, HLA Antigens immunology, Humans, Isoantibodies blood, Kaplan-Meier Estimate, Male, Middle Aged, Retrospective Studies, Risk Assessment, Risk Factors, Time Factors, Treatment Outcome, Young Adult, Antibodies, Monoclonal administration & dosage, Graft Rejection prevention & control, Graft Survival drug effects, Immunity, Humoral drug effects, Immunosuppressive Agents administration & dosage, Kidney Transplantation adverse effects, Kidney Transplantation immunology, Kidney Transplantation mortality, Receptors, Interleukin-2 antagonists & inhibitors, Recombinant Fusion Proteins administration & dosage
- Abstract
Low-risk renal transplant recipients treated with standard immunosuppressive therapy including interleukin-2 receptor (IL-2R) antagonist show a low incidence of early rejection episodes but few reports have examined the incidence and severity of late rejection processes. This study evaluated retrospectively cellular and antibody-mediated rejection (AMR) among 42 recipients selected because they showed low panel-reactive-antibodies, short cold ischemia time, no delayed graft function, and therapy including basiliximab (Simulect) induction. The mean observation time was 6.6 years. Sixty-seven percent of donors were deceased. Ten-year patient and death-censored graft survivals were 81% and 78%, respectively. Seven patients lost their kidneys due to nonimmunologic events. The seven recipients who experienced cellular rejection episodes during the first posttransplant year had them reversed with steroids. Five patients displayed late acute AMR causing functional deterioration in four cases including 1 graft loss. De novo sensitization occurred in 48% of recipients including patients without clinical rejection. In conclusion, long-term follow-up of kidney transplant recipients selected by a low immunologic risk showed a persistent risk of de novo sensitization evolving to acute AMR in 11% of cases. Although immunologic events were related to late immunosuppressive reduction, most graft losses were due to nonimmunologic factors., (Copyright © 2011 Elsevier Inc. All rights reserved.)
- Published
- 2011
- Full Text
- View/download PDF